Charles Schwab’s ADC Therapeutics ADCT Stock Holding History

Charles Schwab’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$240K	Sell	224,058 -303	-0.1%	-$884	﹤0.01%	3356
2026 Q1	$841K	Buy	224,361 +11,693	+5%	+$46.1K	﹤0.01%	2949
2025 Q4	$751K	Buy	212,668 +30,656	+17%	+$124K	﹤0.01%	3020
2025 Q3	$728K	Hold	182,012	–	–	﹤0.01%	3052
2025 Q2	$488K	Sell	182,012 -12,246	-6%	-$25.8K	﹤0.01%	3146
2025 Q1	$274K	Hold	194,258	–	–	﹤0.01%	3224
2024 Q4	$387K	Hold	194,258	–	–	﹤0.01%	3211
2024 Q3	$612K	Buy	194,258 +18,796	+11%	+$59.3K	﹤0.01%	3090
2024 Q2	$554K	Buy	+175,462	New	+$697K	﹤0.01%	3151

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Charles Schwab's ADCT Position: Q2 2026 in Review

Charles Schwab reduced its ADC Therapeutics (ADCT) stake by 0.14% in Q2 2026, selling an estimated $884 and leaving 224,058 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #3356.

Charles Schwab first reported a position in ADCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $841K in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Charles Schwab held 224,058 shares of ADC Therapeutics worth $240K as of Q2 2026.
Charles Schwab sold 303 ADC Therapeutics shares in Q2 2026, an estimated $884.
ADC Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3356 holding.
Charles Schwab first reported a position in ADC Therapeutics in Q2 2024 and has held it in 9 quarters since.
Charles Schwab's ADC Therapeutics position peaked at $841K in Q1 2026.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.